26 results on '"Tsakiridis, Theodoros"'
Search Results
2. Meta-Analysis of Stereotactic Body Radiation ThERapy in Nonspine BONE Metastases (MASTER-BONES)
3. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
4. Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial
5. The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments
6. A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer
7. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
8. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
9. Metformin-induced reductions in tumor growth involves modulation of the gut microbiome
10. Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells
11. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)
12. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
13. A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)
14. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial
15. Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
16. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
17. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel
18. 40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy
19. 167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy
20. 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer
21. 3 - Mechanisms of Metformin on Colon Cancer Inhibition: Roles of the Gut Microbiome, Butyrate and AMPK
22. 90: Combined Salicylate (SAL) - Metformin (MET) Treatment Induces Increased Tumour Suppression and Radiosensitization in Preclinical Models of Prostate Cancer (PRCA)
23. Metformin for chemo-radio-sensitization of NSCLC
24. NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)
25. Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC)
26. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.